<?xml version="1.0" encoding="UTF-8"?><!-- Normalized for easier text mining. --><xocs:doc xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.elsevier.com/xml/ja/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://schema.elsevier.com/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta><xocs:content-family>serial</xocs:content-family><xocs:content-type>JL</xocs:content-type><xocs:cid>286331</xocs:cid><xocs:srctitle>Stem Cell Reports</xocs:srctitle><xocs:normalized-srctitle>STEMCELLREPORTS</xocs:normalized-srctitle><xocs:orig-load-date>2013-08-29</xocs:orig-load-date><xocs:ew-transaction-id>2014-01-25T04:43:48</xocs:ew-transaction-id><xocs:eid>1-s2.0-S2213671113000672</xocs:eid><xocs:pii-formatted>S2213-6711(13)00067-2</xocs:pii-formatted><xocs:pii-unformatted>S2213671113000672</xocs:pii-unformatted><xocs:doi>10.1016/j.stemcr.2013.08.001</xocs:doi><xocs:item-stage>S300</xocs:item-stage><xocs:item-version-number>S300.2</xocs:item-version-number><xocs:item-weight>FULL-TEXT</xocs:item-weight><xocs:hub-eid>1-s2.0-S2213671113X00049</xocs:hub-eid><xocs:timestamp>2014-02-03T15:49:17.288084-05:00</xocs:timestamp><xocs:issns><xocs:issn-primary-formatted>2213-6711</xocs:issn-primary-formatted><xocs:issn-primary-unformatted>22136711</xocs:issn-primary-unformatted></xocs:issns><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>NONE</xocs:funding-body-id><xocs:crossmark>true</xocs:crossmark><xocs:vol-first>1</xocs:vol-first><xocs:iss-first>3</xocs:iss-first><xocs:vol-iss-suppl-text>Volume 1, Issue 3</xocs:vol-iss-suppl-text><xocs:sort-order>3</xocs:sort-order><xocs:first-fp>226</xocs:first-fp><xocs:last-lp>234</xocs:last-lp><xocs:pages><xocs:first-page>226</xocs:first-page><xocs:last-page>234</xocs:last-page></xocs:pages><xocs:cover-date-orig><xocs:start-date>20130910</xocs:start-date></xocs:cover-date-orig><xocs:cover-date-text>10 September 2013</xocs:cover-date-text><xocs:cover-date-start>2013-09-10</xocs:cover-date-start><xocs:cover-date-year>2013</xocs:cover-date-year><xocs:hub-sec><xocs:hub-sec-title>Reports</xocs:hub-sec-title></xocs:hub-sec><xocs:document-type>article</xocs:document-type><xocs:document-subtype>sco</xocs:document-subtype><xocs:copyright-line>Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.</xocs:copyright-line><xocs:normalized-article-title>GENETICCORRECTIONTAUOPATHYPHENOTYPESINNEURONSDERIVEDHUMANINDUCEDPLURIPOTENTSTEMCELLS</xocs:normalized-article-title><xocs:normalized-first-auth-surname>FONG</xocs:normalized-first-auth-surname><xocs:normalized-first-auth-initial>H</xocs:normalized-first-auth-initial><xocs:item-toc><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Results</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Generation of iPSCs from an Individual with a TAU-A152T Mutation</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Generation of Isogenic TAU-A152T-iPSC Lines</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Isogenic TAU-A152T-iPSC Lines Have Similar Genetic and Neural Stem Cell Differentiation Properties</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Genetic Correction of TAU-A152T Mutation Abolishes and Homozygous TAU-A152T Mutation Intensifies Tauopathy Phenotypes</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Genetic Correction of TAU-A152T Mutation Eliminates and Homozygous TAU-A152T Mutation Intensifies the Generation of Pathological TAU Fragments in Neurons</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Genetic Correction of TAU-A152T Eliminates the Detrimental Effects of the Mutation on Different Subtypes of Neurons</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Discussion</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Experimental Procedures</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Reprogramming Human Dermal Fibroblasts into iPSCs</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Preparation of ZFNs and Generation of Isogenic iPSC Lines</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Neuronal Differentiation of iPSCs</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Human Neuropathology</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Statistical Analyses</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:acknowledgment"><xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:appendices"><xocs:item-toc-section-title>Supplemental Information</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:bibliography"><xocs:item-toc-section-title>References</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc><xocs:references><xocs:ref-info refid="sref1"><xocs:ref-normalized-surname>AN</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>253</xocs:ref-first-fp><xocs:ref-last-lp>263</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref2"><xocs:ref-normalized-surname>ASHE</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>631</xocs:ref-first-fp><xocs:ref-last-lp>645</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref3"><xocs:ref-normalized-surname>CARMEL</xocs:ref-normalized-surname><xocs:ref-pub-year>1996</xocs:ref-pub-year><xocs:ref-first-fp>32789</xocs:ref-first-fp><xocs:ref-last-lp>32795</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref4"><xocs:ref-normalized-surname>CHAMBERS</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>275</xocs:ref-first-fp><xocs:ref-last-lp>280</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref5"><xocs:ref-normalized-surname>HDIPSCCONSORTIUM</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>264</xocs:ref-first-fp><xocs:ref-last-lp>278</xocs:ref-last-lp></xocs:ref-info><xocs:ref-info refid="sref6"><xocs:ref-normalized-surname>COPPOLA</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>3500</xocs:ref-first-fp><xocs:ref-last-lp>3512</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref7"><xocs:ref-normalized-surname>CORTI</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref8"><xocs:ref-normalized-surname>FONG</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>333</xocs:ref-first-fp><xocs:ref-last-lp>341</xocs:ref-last-lp><xocs:ref-normalized-initial>H</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref9"><xocs:ref-normalized-surname>GAMBLIN</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>10032</xocs:ref-first-fp><xocs:ref-last-lp>10037</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref10"><xocs:ref-normalized-surname>GOEDERT</xocs:ref-normalized-surname><xocs:ref-pub-year>1989</xocs:ref-pub-year><xocs:ref-first-fp>519</xocs:ref-first-fp><xocs:ref-last-lp>526</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref11"><xocs:ref-normalized-surname>GUILLOZETBONGAARTS</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>1015</xocs:ref-first-fp><xocs:ref-last-lp>1022</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref12"><xocs:ref-normalized-surname>HEVNER</xocs:ref-normalized-surname><xocs:ref-pub-year>2001</xocs:ref-pub-year><xocs:ref-first-fp>353</xocs:ref-first-fp><xocs:ref-last-lp>366</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref13"><xocs:ref-normalized-surname>HOCKEMEYER</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>851</xocs:ref-first-fp><xocs:ref-last-lp>857</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref14"><xocs:ref-normalized-surname>HU</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>1295</xocs:ref-first-fp><xocs:ref-last-lp>1304</xocs:ref-last-lp><xocs:ref-normalized-initial>B</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref15"><xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>1204</xocs:ref-first-fp><xocs:ref-last-lp>1222</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref16"><xocs:ref-normalized-surname>HUTTON</xocs:ref-normalized-surname><xocs:ref-pub-year>2000</xocs:ref-pub-year><xocs:ref-first-fp>63</xocs:ref-first-fp><xocs:ref-last-lp>73</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref17"><xocs:ref-normalized-surname>ISRAEL</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>216</xocs:ref-first-fp><xocs:ref-last-lp>220</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref18"><xocs:ref-normalized-surname>KARA</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>e7</xocs:ref-first-fp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref19"><xocs:ref-normalized-surname>KONDO</xocs:ref-normalized-surname><xocs:ref-pub-year>2013</xocs:ref-pub-year><xocs:ref-first-fp>487</xocs:ref-first-fp><xocs:ref-last-lp>496</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref20"><xocs:ref-normalized-surname>KOSIK</xocs:ref-normalized-surname><xocs:ref-pub-year>1986</xocs:ref-pub-year><xocs:ref-first-fp>4044</xocs:ref-first-fp><xocs:ref-last-lp>4048</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref21"><xocs:ref-normalized-surname>KOSIK</xocs:ref-normalized-surname><xocs:ref-pub-year>1989</xocs:ref-pub-year><xocs:ref-first-fp>1389</xocs:ref-first-fp><xocs:ref-last-lp>1397</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref22"><xocs:ref-normalized-surname>KOVACS</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>3</xocs:ref-first-fp><xocs:ref-last-lp>10</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref23"><xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname><xocs:ref-pub-year>2001</xocs:ref-pub-year><xocs:ref-first-fp>1121</xocs:ref-first-fp><xocs:ref-last-lp>1159</xocs:ref-last-lp><xocs:ref-normalized-initial>V</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref24"><xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>615</xocs:ref-first-fp><xocs:ref-last-lp>619</xocs:ref-last-lp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref25"><xocs:ref-normalized-surname>MANDELKOW</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>a006247</xocs:ref-first-fp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref26"><xocs:ref-normalized-surname>MILLER</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>778</xocs:ref-first-fp><xocs:ref-last-lp>785</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref27"><xocs:ref-normalized-surname>MORRIS</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>410</xocs:ref-first-fp><xocs:ref-last-lp>426</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref28"><xocs:ref-normalized-surname>MURPHY</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>607</xocs:ref-first-fp><xocs:ref-last-lp>610</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref29"><xocs:ref-normalized-surname>NEVE</xocs:ref-normalized-surname><xocs:ref-pub-year>1986</xocs:ref-pub-year><xocs:ref-first-fp>271</xocs:ref-first-fp><xocs:ref-last-lp>280</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref30"><xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>877</xocs:ref-first-fp><xocs:ref-last-lp>886</xocs:ref-last-lp><xocs:ref-normalized-initial>I</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref31"><xocs:ref-normalized-surname>PORZIG</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>644</xocs:ref-first-fp><xocs:ref-last-lp>649</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref32"><xocs:ref-normalized-surname>RING</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>100</xocs:ref-first-fp><xocs:ref-last-lp>109</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref33"><xocs:ref-normalized-surname>SOLDNER</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>318</xocs:ref-first-fp><xocs:ref-last-lp>331</xocs:ref-last-lp><xocs:ref-normalized-initial>F</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref34"><xocs:ref-normalized-surname>TAKAHASHI</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>663</xocs:ref-first-fp><xocs:ref-last-lp>676</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref35"><xocs:ref-normalized-surname>TAKAHASHI</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>861</xocs:ref-first-fp><xocs:ref-last-lp>872</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref36"><xocs:ref-normalized-surname>VOSSEL</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>708</xocs:ref-first-fp><xocs:ref-last-lp>716</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref37"><xocs:ref-normalized-surname>WEDER</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>15</xocs:ref-first-fp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="sref38"><xocs:ref-normalized-surname>YAMANAKA</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>13</xocs:ref-first-fp><xocs:ref-last-lp>17</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info></xocs:references><xocs:attachment-metadata-doc><xocs:attachment-set-type>item</xocs:attachment-set-type><xocs:pii-formatted>S2213-6711(13)00067-2</xocs:pii-formatted><xocs:pii-unformatted>S2213671113000672</xocs:pii-unformatted><xocs:eid>1-s2.0-S2213671113000672</xocs:eid><xocs:doi>10.1016/j.stemcr.2013.08.001</xocs:doi><xocs:cid>286331</xocs:cid><xocs:timestamp>2014-01-25T05:35:55.170352-05:00</xocs:timestamp><xocs:path>/286331/1-s2.0-S2213671113X00049/1-s2.0-S2213671113000672/</xocs:path><xocs:cover-date-start>2013-09-10</xocs:cover-date-start><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>NONE</xocs:funding-body-id><xocs:attachments><xocs:web-pdf><xocs:attachment-eid>1-s2.0-S2213671113000672-main.pdf</xocs:attachment-eid><xocs:filename>main.pdf</xocs:filename><xocs:extension>pdf</xocs:extension><xocs:pdf-optimized>true</xocs:pdf-optimized><xocs:filesize>3304170</xocs:filesize><xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose><xocs:web-pdf-page-count>9</xocs:web-pdf-page-count><xocs:web-pdf-images><xocs:web-pdf-image><xocs:attachment-eid>1-s2.0-S2213671113000672-main_1.png</xocs:attachment-eid><xocs:filename>main_1.png</xocs:filename><xocs:extension>png</xocs:extension><xocs:filesize>123727</xocs:filesize><xocs:pixel-height>849</xocs:pixel-height><xocs:pixel-width>656</xocs:pixel-width><xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type><xocs:pdf-page-num>1</xocs:pdf-page-num></xocs:web-pdf-image></xocs:web-pdf-images></xocs:web-pdf><xocs:attachment><xocs:attachment-eid>1-s2.0-S2213671113000672-gr3.jpg</xocs:attachment-eid><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>216969</xocs:filesize><xocs:pixel-height>793</xocs:pixel-height><xocs:pixel-width>638</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2213671113000672-gr4.jpg</xocs:attachment-eid><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>99217</xocs:filesize><xocs:pixel-height>468</xocs:pixel-height><xocs:pixel-width>657</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2213671113000672-gr2.jpg</xocs:attachment-eid><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>169906</xocs:filesize><xocs:pixel-height>791</xocs:pixel-height><xocs:pixel-width>656</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2213671113000672-gr1.jpg</xocs:attachment-eid><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>114982</xocs:filesize><xocs:pixel-height>791</xocs:pixel-height><xocs:pixel-width>373</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2213671113000672-gr3.sml</xocs:attachment-eid><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>11507</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>132</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2213671113000672-gr4.sml</xocs:attachment-eid><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>13133</xocs:filesize><xocs:pixel-height>156</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2213671113000672-gr2.sml</xocs:attachment-eid><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>9700</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>136</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2213671113000672-gr1.sml</xocs:attachment-eid><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>6643</xocs:filesize><xocs:pixel-height>163</xocs:pixel-height><xocs:pixel-width>77</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2213671113000672-mmc1.pdf</xocs:attachment-eid><xocs:file-basename>mmc1</xocs:file-basename><xocs:filename>mmc1.pdf</xocs:filename><xocs:extension>pdf</xocs:extension><xocs:filesize>852245</xocs:filesize><xocs:attachment-type>APPLICATION</xocs:attachment-type></xocs:attachment></xocs:attachments></xocs:attachment-metadata-doc><xocs:refkeys><xocs:refkey3>FONGX2013X226</xocs:refkey3><xocs:refkey4lp>FONGX2013X226X234</xocs:refkey4lp><xocs:refkey4ai>FONGX2013X226XH</xocs:refkey4ai><xocs:refkey5>FONGX2013X226X234XH</xocs:refkey5></xocs:refkeys><xocs:open-access><xocs:oa-article-status is-open-access="1" is-open-archive="0">Full</xocs:oa-article-status><xocs:oa-access-effective-date>2013-08-01T19:23:40Z</xocs:oa-access-effective-date><xocs:oa-sponsor><xocs:oa-sponsor-type>ElsevierWaived</xocs:oa-sponsor-type></xocs:oa-sponsor><xocs:oa-user-license>http://creativecommons.org/licenses/by/3.0/</xocs:oa-user-license></xocs:open-access></xocs:meta><xocs:serial-item><article xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" docsubtype="sco" version="5.2" xml:lang="en"><item-info><jid>STEMCR</jid><aid>26</aid><ce:pii>S2213-6711(13)00067-2</ce:pii><ce:doi>10.1016/j.stemcr.2013.08.001</ce:doi><ce:copyright type="other" year="2013">The Authors</ce:copyright></item-info><ce:floats><ce:figure id="fig1"><ce:label>Figure 1</ce:label><ce:caption id="cap0010"><ce:simple-para id="fspara0010" view="all">Generation of Isogenic Human TAU-A152T-iPSC Lines with ZFN-Mediated Gene-Editing Technology</ce:simple-para><ce:simple-para id="fspara0015" view="all">(A) Schematic of ZFN-mediated correction of the TAU-A152T mutation.</ce:simple-para><ce:simple-para id="fspara0020" view="all">(B) Screening of iPSCs with genetic correction of the TAU-A152T mutation by HphI restriction digestion of a TAU PCR product from genomic DNA (gDNA) of different iPSC clones. Sequencing of the gDNA from the isogenic TAU-152A/A-iPSCs confirmed correction of the nucleotide from A to G at the original mutation site (red arrows). For more information, see <ce:cross-ref refid="app2" id="crosref0465">Figure S1</ce:cross-ref>.</ce:simple-para><ce:simple-para id="fspara0025" view="all">(C) Screening of iPSCs with engineered homozygous TAU-A152T mutation by HphI restriction digestion of a TAU PCR product from gDNA of different iPSC clones. Sequencing of the gDNA from the isogenic TAU-152T/T-iPSCs confirmed the change in nucleotide from G to A to generate a homozygous mutation (red arrows). For more information, see <ce:cross-ref refid="app2" id="crosref0470">Figure S1</ce:cross-ref>.</ce:simple-para><ce:simple-para id="fspara0030" view="all">(D-L) Isogenic TAU-A152T-iPSCs demonstrated similar ES cell morphology (D, G, and J) and stained positive for pluripotency markers Oct4 (E, H, and K) and Sox2 (F, I, and L).</ce:simple-para><ce:simple-para id="fspara0035" view="all">Scale bars represent 50 μm. See also <ce:cross-ref refid="app2" id="crosref0475">Figure S1</ce:cross-ref>.</ce:simple-para></ce:caption><ce:link locator="gr1"/></ce:figure><ce:figure id="fig2"><ce:label>Figure 2</ce:label><ce:caption id="cap0015"><ce:simple-para id="fspara0040" view="all">Characterization of the Isogenic TAU-A152T-iPSC Lines</ce:simple-para><ce:simple-para id="fspara0045" view="all">(A-C) Karyotype and G-band analysis confirmed a normal 46, XY karyotype in all three isogenic TAU-A152T-iPSC lines.</ce:simple-para><ce:simple-para id="fspara0050" view="all">(D-F) Global gene expression profiling demonstrated very few variations among all three isogenic TAU-A152T-iPSC lines.</ce:simple-para><ce:simple-para id="fspara0055" view="all">(G-K) All three isogenic TAU-A152T-iPSC lines generated neurospheres at similar levels and of comparable sizes.</ce:simple-para><ce:simple-para id="fspara0060" view="all">(L-N) Stable NSCs expressing the neural precursor markers Sox2 (green) and Nestin (red) could be generated equally well from all three isogenic TAU-A152T-iPSC lines.</ce:simple-para><ce:simple-para id="fspara0065" view="all">Values are mean ± SD. Scale bars represent 100 μm (G-I) and 50 μm (L-N).</ce:simple-para></ce:caption><ce:link locator="gr2"/></ce:figure><ce:figure id="fig3"><ce:label>Figure 3</ce:label><ce:caption id="cap0020"><ce:simple-para id="fspara0070" view="all">Genetic Correction of TAU-A152T Mutation Abolishes and Homozygous TAU-A152T Mutation Intensifies Tauopathy Phenotypes in iPSC-Derived Neurons as Determined by Immunocytochemistry</ce:simple-para><ce:simple-para id="fspara0075" view="all">(A-F) Mild neurodegeneration and accumulation of punctate TAU were found in neurons derived from TAU-152A/T-iPSCs (B and E), which were abolished in the mutation-corrected TAU-152A/A-iPSC-derived neurons (A and D) and intensified in homozygous TAU-152T/T-iPSC-derived neurons (C and F).</ce:simple-para><ce:simple-para id="fspara0080" view="all">(G and H) High magnification of TAU-152T/T-iPSC-derived neurons showed severe axonal degeneration with the accumulation of punctate TAU (H), which was completely rescued by genetic correction of the mutation in TAU-152A/A-iPSC-derived neurons (G).</ce:simple-para><ce:simple-para id="fspara0085" view="all">(I-L) AT8-positive phosphorylated TAU (p-TAU) was found in the axons of some neurons from TAU-152A/T-iPSCs (J, green). This phenotype was intensified in the axons and cell soma of neurons derived from TAU-152T/T-iPSCs (K and L, green). Correction of the mutation eliminates the phenotype as evidenced by little to no p-TAU in neurons derived from TAU-152A/A-iPSCs (I). All neurons were also costained for total TAU (red).</ce:simple-para><ce:simple-para id="fspara0090" view="all">(M) Quantification of AT8-positive neurons derived from the isogenic TAU-A152T-iPSC lines.</ce:simple-para><ce:simple-para id="fspara0095" view="all">(N-P) Caspase-cleaved TAU (C3) was found in the axons of neurons derived from TAU-152A/T-iPSCs (O), which was intensified in neurons derived from TAU-152T/T-iPSCs (P), but not in neurons derived from TAU-152A/A-iPSCs (N).</ce:simple-para><ce:simple-para id="fspara0100" view="all">(Q) Quantification of C3-positive neurons derived from the isogenic TAU-A152T-iPSC lines.</ce:simple-para><ce:simple-para id="fspara0105" view="all">(R-U) Caspase-cleaved TAU (C3, green) and p-TAU (red) were also found in the axons and cell soma of neurons from a patient with PSP carrying the TAU-A152T mutation.</ce:simple-para><ce:simple-para id="fspara0110" view="all">Values are mean ± SD. Scale bars represent 30 μm (A-F, I-L, and N-P), 5 μm (G and H), and 10 μm (R-U).</ce:simple-para><ce:simple-para id="fspara0115" view="all">See also <ce:cross-ref refid="app2" id="crosref0480">Figure S2</ce:cross-ref>.</ce:simple-para></ce:caption><ce:link locator="gr3"/></ce:figure><ce:figure id="fig4"><ce:label>Figure 4</ce:label><ce:caption id="cap0025"><ce:simple-para id="fspara0120" view="all">Genetic Correction of TAU-A152T Mutation Abolishes and Homozygous TAU-A152T Mutation Intensifies Tauopathy Phenotypes in iPSC-Derived Neurons as Determined by Western Blotting</ce:simple-para><ce:simple-para id="fspara0125" view="all">(A and B) Western blotting with the TAU-5 antibody revealed more TAU fragmentation in neurons derived from the parental TAU-152A/T-iPSCs than in neurons derived from control iPSCs without the mutation (A). Quantification of TAU bands showed a significantly greater amount of total fragments of TAU in TAU-152A/T-iPSC-derived neurons than in the control iPSC-derived neurons (B).</ce:simple-para><ce:simple-para id="fspara0130" view="all">(C) Western blotting with the TAU-5 antibody also revealed increased fragmentation of the TAU protein (arrows) in the brain lysate of a patient with PSP carrying the TAU-A152T mutation.</ce:simple-para><ce:simple-para id="fspara0135" view="all">(D-I) Western blotting with an antibody against the central part (D and E, TAU-5), the N terminus (F and G, TAU-A12), or the C terminus (H and I, TAU-C17) of the TAU protein confirmed the increases in TAU fragmentation in neurons derived from TAU-152A/T-iPSCs and TAU-152T/T-iPSCs. The numbers and amounts of TAU fragmentations were dramatically less upon genetic correction of the mutation.</ce:simple-para><ce:simple-para id="fspara0140" view="all">(J and K) A mutant gene-dose-dependent increase of caspase-cleaved TAU (TAU-C3) was observed in neurons derived from the three isogenic TAU-152A/T-iPSC lines.</ce:simple-para><ce:simple-para id="fspara0145" view="all">(L and M) Higher levels of AT8-positive p-TAU at two molecular masses (&gt;250 and ∼74 kDa) were found in neurons derived from TAU-152A/T-iPSCs and TAU-152T/T-iPSCs than in neurons derived from TAU-152A/A-iPSCs.</ce:simple-para><ce:simple-para id="fspara0150" view="all">All TAU band quantifications were normalized to total TAU. Values are mean ± SD. <ce:sup loc="pre">∗</ce:sup>p ≤ 0.05, <ce:sup loc="pre">∗∗</ce:sup>p ≤ 0.01.</ce:simple-para></ce:caption><ce:link locator="gr4"/></ce:figure></ce:floats><head><ce:article-footnote><ce:note-para id="ntpara0010" view="all">This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</ce:note-para></ce:article-footnote><ce:dochead id="dhead0010"><ce:textfn>Report</ce:textfn></ce:dochead><ce:title id="title0010">Genetic Correction of Tauopathy Phenotypes in Neurons Derived from Human Induced Pluripotent Stem Cells</ce:title><ce:author-group id="augrp0010"><ce:author id="au1"><ce:given-name>Helen</ce:given-name><ce:surname>Fong</ce:surname><ce:cross-ref refid="aff1" id="crosref0010"><ce:sup loc="post">1</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2" id="crosref0015"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:author><ce:author id="au2"><ce:given-name>Chengzhong</ce:given-name><ce:surname>Wang</ce:surname><ce:cross-ref refid="aff1" id="crosref0020"><ce:sup loc="post">1</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2" id="crosref0025"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:author><ce:author id="au3"><ce:given-name>Johanna</ce:given-name><ce:surname>Knoferle</ce:surname><ce:cross-ref refid="aff1" id="crosref0030"><ce:sup loc="post">1</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2" id="crosref0035"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:author><ce:author id="au4"><ce:given-name>David</ce:given-name><ce:surname>Walker</ce:surname><ce:cross-ref refid="aff1" id="crosref0040"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author id="au5"><ce:given-name>Maureen E.</ce:given-name><ce:surname>Balestra</ce:surname><ce:cross-ref refid="aff1" id="crosref0045"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author id="au6"><ce:given-name>Leslie M.</ce:given-name><ce:surname>Tong</ce:surname><ce:cross-ref refid="aff1" id="crosref0050"><ce:sup loc="post">1</ce:sup></ce:cross-ref><ce:cross-ref refid="aff3" id="crosref0055"><ce:sup loc="post">3</ce:sup></ce:cross-ref></ce:author><ce:author id="au7"><ce:given-name>Laura</ce:given-name><ce:surname>Leung</ce:surname><ce:cross-ref refid="aff1" id="crosref0060"><ce:sup loc="post">1</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2" id="crosref0065"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:author><ce:author id="au8"><ce:given-name>Karen L.</ce:given-name><ce:surname>Ring</ce:surname><ce:cross-ref refid="aff1" id="crosref0070"><ce:sup loc="post">1</ce:sup></ce:cross-ref><ce:cross-ref refid="aff3" id="crosref0075"><ce:sup loc="post">3</ce:sup></ce:cross-ref></ce:author><ce:author id="au9"><ce:given-name>William W.</ce:given-name><ce:surname>Seeley</ce:surname><ce:cross-ref refid="aff2" id="crosref0080"><ce:sup loc="post">2</ce:sup></ce:cross-ref><ce:cross-ref refid="aff4" id="crosref0085"><ce:sup loc="post">4</ce:sup></ce:cross-ref></ce:author><ce:author id="au10"><ce:given-name>Anna</ce:given-name><ce:surname>Karydas</ce:surname><ce:cross-ref refid="aff2" id="crosref0090"><ce:sup loc="post">2</ce:sup></ce:cross-ref><ce:cross-ref refid="aff4" id="crosref0095"><ce:sup loc="post">4</ce:sup></ce:cross-ref></ce:author><ce:author id="au11"><ce:given-name>Mihir A.</ce:given-name><ce:surname>Kshirsagar</ce:surname><ce:cross-ref refid="aff1" id="crosref0100"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author id="au12"><ce:given-name>Adam L.</ce:given-name><ce:surname>Boxer</ce:surname><ce:cross-ref refid="aff2" id="crosref0105"><ce:sup loc="post">2</ce:sup></ce:cross-ref><ce:cross-ref refid="aff4" id="crosref0110"><ce:sup loc="post">4</ce:sup></ce:cross-ref></ce:author><ce:author id="au13"><ce:given-name>Kenneth S.</ce:given-name><ce:surname>Kosik</ce:surname><ce:cross-ref refid="aff6" id="crosref0115"><ce:sup loc="post">6</ce:sup></ce:cross-ref></ce:author><ce:author id="au14"><ce:given-name>Bruce L.</ce:given-name><ce:surname>Miller</ce:surname><ce:cross-ref refid="aff2" id="crosref0120"><ce:sup loc="post">2</ce:sup></ce:cross-ref><ce:cross-ref refid="aff4" id="crosref0125"><ce:sup loc="post">4</ce:sup></ce:cross-ref></ce:author><ce:author id="au15"><ce:given-name>Yadong</ce:given-name><ce:surname>Huang</ce:surname><ce:cross-ref refid="aff1" id="crosref0130"><ce:sup loc="post">1</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2" id="crosref0135"><ce:sup loc="post">2</ce:sup></ce:cross-ref><ce:cross-ref refid="aff3" id="crosref0140"><ce:sup loc="post">3</ce:sup></ce:cross-ref><ce:cross-ref refid="aff5" id="crosref0145"><ce:sup loc="post">5</ce:sup></ce:cross-ref><ce:cross-ref refid="cor1" id="crosref0150"><ce:sup loc="post">∗</ce:sup></ce:cross-ref><ce:e-address type="email" id="eadd0010">yhuang@gladstone.ucsf.edu</ce:e-address></ce:author><ce:affiliation id="aff1"><ce:label>1</ce:label><ce:textfn>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA</ce:textfn></ce:affiliation><ce:affiliation id="aff2"><ce:label>2</ce:label><ce:textfn>Department of Neurology, University of California, San Francisco, CA 94143, USA</ce:textfn></ce:affiliation><ce:affiliation id="aff3"><ce:label>3</ce:label><ce:textfn>Biomedical Sciences Graduate Program, University of California, San Francisco, CA 94143, USA</ce:textfn></ce:affiliation><ce:affiliation id="aff4"><ce:label>4</ce:label><ce:textfn>Memory and Aging Center, University of California, San Francisco, CA 94143, USA</ce:textfn></ce:affiliation><ce:affiliation id="aff5"><ce:label>5</ce:label><ce:textfn>Department of Pathology, University of California, San Francisco, CA 94143, USA</ce:textfn></ce:affiliation><ce:affiliation id="aff6"><ce:label>6</ce:label><ce:textfn>Neuroscience Research Institute and Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA 93106, USA</ce:textfn></ce:affiliation><ce:correspondence id="cor1"><ce:label>∗</ce:label><ce:text>Corresponding author</ce:text></ce:correspondence></ce:author-group><ce:date-received day="25" month="3" year="2013"/><ce:date-revised day="31" month="7" year="2013"/><ce:date-accepted day="1" month="8" year="2013"/><ce:miscellaneous id="misc0010">Published: August 29, 2013</ce:miscellaneous><ce:abstract id="abs0010" view="all" class="author"><ce:section-title id="sectitle0010">Summary</ce:section-title><ce:abstract-sec id="abssec0010" view="all"><ce:simple-para id="abspara0010" view="all">Tauopathies represent a group of neurodegenerative disorders characterized by the accumulation of pathological TAU protein in brains. We report a human neuronal model of tauopathy derived from induced pluripotent stem cells (iPSCs) carrying a TAU-A152T mutation. Using zinc-finger nuclease-mediated gene editing, we generated two isogenic iPSC lines: one with the mutation corrected, and another with the homozygous mutation engineered. The A152T mutation increased TAU fragmentation and phosphorylation, leading to neurodegeneration and especially axonal degeneration. These cellular phenotypes were consistent with those observed in a patient with TAU-A152T. Upon mutation correction, normal neuronal and axonal morphologies were restored, accompanied by decreases in TAU fragmentation and phosphorylation, whereas the severity of tauopathy was intensified in neurons with the homozygous mutation. These isogenic TAU-iPSC lines represent a critical advancement toward the accurate modeling and mechanistic study of tauopathies with human neurons and will be invaluable for drug-screening efforts and future cell-based therapies.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract class="author-highlights" id="abs0015" view="all"><ce:section-title id="sectitle0015">Highlights</ce:section-title><ce:abstract-sec id="abssec0015" view="all"><ce:simple-para id="abspara0015" view="all"><ce:list id="ulist0010"><ce:list-item id="u0010"><ce:label>•</ce:label><ce:para id="p0010" view="all">A human neuron model of tauopathy using TAU-A152T-iPSCs</ce:para></ce:list-item><ce:list-item id="u0015"><ce:label>•</ce:label><ce:para id="p0015" view="all">Correction of TAU-A152T mutation eliminates tauopathy</ce:para></ce:list-item><ce:list-item id="u0020"><ce:label>•</ce:label><ce:para id="p0020" view="all">Engineered homozygous TAU-A152T mutation intensifies tauopathy</ce:para></ce:list-item><ce:list-item id="u0025"><ce:label>•</ce:label><ce:para id="p0025" view="all">A152T mutation increases TAU proteolysis, leading to tauopathy</ce:para></ce:list-item></ce:list></ce:simple-para></ce:abstract-sec></ce:abstract></head><body view="all"><ce:sections><ce:section id="sec1" view="all"><ce:section-title id="sectitle0020">Introduction</ce:section-title><ce:para id="p0030" view="all">Tauopathies are a group of neurodegenerative disorders characterized by the accumulation and aggregation of the pathological TAU protein in human brains (<ce:cross-refs refid="bib16 bib23 bib25 bib36" id="crosrefs0010">Hutton, 2000; Lee et al., 2001; Mandelkow and Mandelkow, 2012; Vossel and Miller, 2008</ce:cross-refs>). TAU, encoded by the <ce:italic>MAPT</ce:italic> gene on chromosome 17, is a microtubule binding protein that is highly expressed in neurons and predominantly located in neuronal axons (<ce:cross-refs refid="bib10 bib21 bib27 bib29" id="crosrefs0015">Goedert et al., 1989; Kosik et al., 1989; Morris et al., 2011; Neve et al., 1986</ce:cross-refs>). Hyperphosphorylation and aggregation of TAU cause neurofibrillary pathologies, including tangles and neuropil threads that are often seen in brains of patients with Alzheimer's disease (AD) (<ce:cross-refs refid="bib16 bib20 bib23 bib25 bib36" id="crosrefs0020">Hutton, 2000; Kosik et al., 1986; Lee et al., 2001; Mandelkow and Mandelkow, 2012; Vossel and Miller, 2008</ce:cross-refs>). Tauopathies are also typical of other neurodegenerative disorders, including frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP) (<ce:cross-refs refid="bib16 bib23 bib25 bib36" id="crosrefs0025">Hutton, 2000; Lee et al., 2001; Mandelkow and Mandelkow, 2012; Vossel and Miller, 2008</ce:cross-refs>). Most FTD and PSP cases are sporadic, but a minority are familial (<ce:cross-ref refid="bib37" id="crosref0155">Weder et al., 2007</ce:cross-ref>). FTD and PSP syndromes can be caused by mutations in the <ce:italic>MAPT</ce:italic> gene that result in abnormal TAU phosphorylation and aggregation, leading to neurodegeneration.</ce:para><ce:para id="p0035" view="all">Transgenic murine models of tauopathies have revealed fundamental insights into the disease (<ce:cross-refs refid="bib23 bib25" id="crosrefs0030">Lee et al., 2001; Mandelkow and Mandelkow, 2012</ce:cross-refs>), but their value as predictive preclinical models is unknown. In fact, many candidate drugs successful in rodent models of neurodegenerative diseases have failed in humans (<ce:cross-refs refid="bib2 bib15" id="crosrefs0035">Ashe and Zahs, 2010; Huang and Mucke, 2012</ce:cross-refs>). Thus, new humanized disease models, such as mutation- and patient-specific induced pluripotent stem cells (iPSCs), are urgently needed for further development of therapeutic strategies for tauopathies.</ce:para><ce:para id="p0040" view="all">Human iPSCs are a highly promising approach for investigating cellular properties of traditionally challenging neurodegenerative disorders (<ce:cross-refs refid="bib5 bib17 bib19 bib30 bib38" id="crosrefs0040">HD iPSC Consortium, 2012; Israel et al., 2012; Kondo et al., 2013; Park et al., 2008; Yamanaka, 2009</ce:cross-refs>). Because postmortem tissue represents late-stage disease, modeling tauopathy onset and progression are problematic with autopsy samples alone. iPSC-derived neurons grown in culture allow for the detection of specific molecular and temporal signatures from mutation-carrying patients, thereby improving our understanding of the pathogenesis of tauopathies.</ce:para><ce:para id="p0045" view="all">One limitation of using iPSCs is the inability to carry out studies under genetically defined conditions, leading to increased experimental variability. To overcome these obstacles, we used a zinc-finger-nuclease (ZFN)-mediated gene-editing technique (<ce:cross-refs refid="bib1 bib7 bib24 bib33" id="crosrefs0045">An et al., 2012; Corti et al., 2012; Li et al., 2012; Soldner et al., 2011</ce:cross-refs>) to generate isogenic human iPSC lines from an individual carrying a TAU-A152T mutation. We demonstrate that isogenic TAU-iPSCs are not only useful for modeling tauopathies, but also for identifying unknown molecular mechanisms underlying the disease-causing mutations.</ce:para></ce:section><ce:section id="sec2" view="all"><ce:section-title id="sectitle0025">Results</ce:section-title><ce:section id="sec2.1" view="all"><ce:section-title id="sectitle0030">Generation of iPSCs from an Individual with a TAU-A152T Mutation</ce:section-title><ce:para id="p0050" view="all">We generated iPSCs from an individual carrying a heterozygous TAU-A152T mutation (<ce:cross-refs refid="bib6 bib18 bib22" id="crosrefs0050">Coppola et al., 2012; Kara et al., 2012; Kovacs et al., 2011</ce:cross-refs>) using a protocol published previously (<ce:cross-refs refid="bib35 bib34" id="crosrefs0055">Takahashi et al., 2007; Takahashi and Yamanaka, 2006</ce:cross-refs>). The TAU-152A/T-iPSCs had characteristics similar to embryonic stem (ES) cells, including their ES cell-like morphology (<ce:cross-ref refid="fig1" id="crosref0160">Figure 1</ce:cross-ref><ce:float-anchor refid="fig1"/>D) and positive staining for ES cell markers (<ce:cross-ref refid="fig1" id="crosref0165">Figures 1</ce:cross-ref>E and 1F; <ce:cross-ref refid="app2" id="crosref0170">Figures S1</ce:cross-ref>B-S1E available online). DNA sequencing confirmed a heterozygous TAU-A152T mutation (<ce:cross-ref refid="fig1" id="crosref0175">Figure 1</ce:cross-ref>B), and chromosomal analysis revealed a normal karyotype (<ce:cross-ref refid="fig2" id="crosref0180">Figure 2</ce:cross-ref><ce:float-anchor refid="fig2"/>A). The TAU-152A/T-iPSCs formed teratomas in immunodeficient mice (<ce:cross-ref refid="app2" id="crosref0185">Figures S1</ce:cross-ref>N-S1P), confirming their pluripotency.</ce:para></ce:section><ce:section id="sec2.2" view="all"><ce:section-title id="sectitle0035">Generation of Isogenic TAU-A152T-iPSC Lines</ce:section-title><ce:para id="p0055" view="all">We used ZFN-mediated gene-editing technology to generate isogenic TAU-A152T-iPSC lines (<ce:cross-refs refid="bib13 bib26 bib33" id="crosrefs0060">Hockemeyer et al., 2009; Miller et al., 2007; Soldner et al., 2011</ce:cross-refs>). The ZFN was designed to target ∼30 base pairs upstream of the A152T mutation on the <ce:italic>MAPT</ce:italic> gene (<ce:cross-ref refid="fig1" id="crosref0190">Figure 1</ce:cross-ref>A). We also used a 1,500 bp linear donor DNA fragment carrying the wild-type nucleotide sequence at position 152 as a repair template for homologous recombination (<ce:cross-ref refid="fig1" id="crosref0195">Figure 1</ce:cross-ref>A). Alternatively, a donor DNA fragment with a TAU-A152T mutation could be used to generate a homozygous TAU-A152T mutation. To obtain "scarless" genome editing, the donor DNA fragment contained no selection marker or excisable sequence. After nucleofection of the TAU-152-ZFN and the donor DNA fragment into 2 × 10<ce:sup loc="post">6</ce:sup> TAU-152A/T-iPSCs (<ce:cross-ref refid="bib8" id="crosref0200">Fong et al., 2011</ce:cross-ref>), the cells were allowed to recover for 2 days and then were plated in a single-cell format in 96-well plates for 7-14 days.</ce:para><ce:para id="p0060" view="all">Inspection of the DNA sequence of the TAU PCR product revealed two restriction cleavage sites for HphI on the wild-type allele and three sites on the mutant allele (<ce:cross-ref refid="app2" id="crosref0205">Figure S1</ce:cross-ref>A). After screening 107 clones, a corrected clone was identified (<ce:cross-ref refid="fig1" id="crosref0210">Figure 1</ce:cross-ref>B, 152A/A-iPSC). From screening an additional 86 clones, we also found a clone containing a homozygous version of the TAU-A152T mutation, where the mutation was present on both alleles (<ce:cross-ref refid="fig1" id="crosref0215">Figure 1</ce:cross-ref>C, 152T/T-iPSC). DNA sequencing confirmed the correction or homozygous mutation of TAU-A152T in the isogenic iPSC lines (<ce:cross-ref refid="fig1" id="crosref0220">Figures 1</ce:cross-ref>B and 1C). The overall efficiency of TAU-ZFN-mediated gene editing was 1%-1.5%.</ce:para></ce:section><ce:section id="sec2.3" view="all"><ce:section-title id="sectitle0040">Isogenic TAU-A152T-iPSC Lines Have Similar Genetic and Neural Stem Cell Differentiation Properties</ce:section-title><ce:para id="p0065" view="all">Both isogenic TAU-152A/A-iPSC and TAU-152T/T-iPSC lines exhibited similar ES cell morphology to the parental TAU-152A/T-iPSC line and stained positive for pluripotency markers as seen in the parental iPSC line (<ce:cross-ref refid="fig1" id="crosref0225">Figures 1</ce:cross-ref>D-1L and <ce:cross-ref refid="app2" id="crosref0230">S1</ce:cross-ref>B-S1M). Furthermore, the newly generated isogenic iPSC lines had a similar ability as the parental iPSC line to form teratomas in immunodeficient mice (<ce:cross-ref refid="app2" id="crosref0235">Figures S1</ce:cross-ref>N-S1V), suggesting similar pluripotency among all three iPSC lines.</ce:para><ce:para id="p0070" view="all">Karyotyping analysis showed that all three isogenic iPSC lines had a normal 46, XY karyotype (<ce:cross-ref refid="fig2" id="crosref0240">Figures 2</ce:cross-ref>A-2C). Global gene expression profiling of all three lines showed very few differences in gene expression patterns (<ce:cross-ref refid="fig2" id="crosref0245">Figures 2</ce:cross-ref>D-2F). Importantly, all three isogenic iPSC lines had similar abilities to generate neurospheres (<ce:cross-ref refid="fig2" id="crosref0250">Figures 2</ce:cross-ref>G-2K) and neural stem cells positive for Sox2 and Nestin (<ce:cross-ref refid="fig2" id="crosref0255">Figures 2</ce:cross-ref>L-2N).</ce:para></ce:section><ce:section id="sec2.4" view="all"><ce:section-title id="sectitle0045">Genetic Correction of TAU-A152T Mutation Abolishes and Homozygous TAU-A152T Mutation Intensifies Tauopathy Phenotypes</ce:section-title><ce:para id="p0075" view="all">Upon neuronal differentiation of the parental TAU-152A/T-iPSCs (<ce:cross-refs refid="bib4 bib14 bib32" id="crosrefs0065">Chambers et al., 2009; Hu and Zhang, 2009; Ring et al., 2012</ce:cross-refs>), immunocytochemical analysis of TAU revealed unhealthy looking neurons with punctate TAU staining in neuronal processes (<ce:cross-ref refid="fig3" id="crosref0260">Figure 3</ce:cross-ref><ce:float-anchor refid="fig3"/>E). Their neurites were short and tapering and appeared to bulge and constrict with odd bends and breaks (<ce:cross-ref refid="fig3" id="crosref0265">Figure 3</ce:cross-ref>E). MAP2 immunostaining confirmed mild degeneration of neuronal processes (<ce:cross-ref refid="fig3" id="crosref0270">Figure 3</ce:cross-ref>B). Genetic correction of the mutation in the isogenic TAU-152A/A-iPSCs abolished the neurodegenerative phenotype, leading to the generation of healthy looking neurons with smooth TAU and MAP2 staining (<ce:cross-ref refid="fig3" id="crosref0275">Figures 3</ce:cross-ref>A and 3D). In sharp contrast, the isogenic homozygous TAU-152T/T-iPSCs generated neurons with severe degeneration and a much lower survival of neurons, as indicated by MAP2 staining (<ce:cross-ref refid="fig3" id="crosref0280">Figure 3</ce:cross-ref>C), and much more punctate TAU staining in neuronal processes (<ce:cross-ref refid="fig3" id="crosref0285">Figure 3</ce:cross-ref>F). Quantitatively, there was a gene-dose-dependent effect of the TAU-A152T mutation on neurodegeneration as evidenced by abnormal TAU staining (<ce:cross-ref refid="app2" id="crosref0290">Figure S2</ce:cross-ref>A). High-magnification images revealed severe axonal degeneration and fragmentation of neurons derived from TAU-152T/T-iPSCs (<ce:cross-ref refid="fig3" id="crosref0295">Figure 3</ce:cross-ref>H), which was completely rescued by correcting the mutation in the isogenic TAU-152A/A-iPSCs (<ce:cross-ref refid="fig3" id="crosref0300">Figure 3</ce:cross-ref>G). Neurodegeneration was also observed in a subclone of TAU-152T/T-iPSCs (152T/T-2), as evidenced by abnormal TAU staining (<ce:cross-ref refid="app2" id="crosref0305">Figure S2</ce:cross-ref>B). Low-density neuronal culture and double immunostaining for TAU and MAP2 revealed mislocalization of TAU-A152T to the somatodendritic domains in TAU-152T/T-iPSC-derived neurons (<ce:cross-ref refid="app2" id="crosref0310">Figures S2</ce:cross-ref>E and S2F).</ce:para><ce:para id="p0080" view="all">AT8-positive phosphorylated TAU (p-TAU) was found in some neurons derived from TAU-152A/T-iPSCs, with a predominant and punctate location in axons (<ce:cross-ref refid="fig3" id="crosref0315">Figure 3</ce:cross-ref>J). Again, genetic correction of the mutation abolished p-TAU accumulation (<ce:cross-ref refid="fig3" id="crosref0320">Figure 3</ce:cross-ref>I), whereas the homozygous mutation exacerbated p-TAU accumulation in both axons and cell soma (<ce:cross-ref refid="fig3" id="crosref0325">Figures 3</ce:cross-ref>K and 3L). The mutation-related increase in p-TAU was also observed in a subclone of TAU-152T/T-iPSC-derived neurons (<ce:cross-ref refid="app2" id="crosref0330">Figure S2</ce:cross-ref>C). Strikingly, the numbers of p-TAU-positive neurons increased in a TAU-A152T gene-dose-dependent manner (<ce:cross-ref refid="fig3" id="crosref0335">Figure 3</ce:cross-ref>M). Accumulation of p-TAU was restricted to neurons as there was no p-TAU in GFAP-positive astrocytes (<ce:cross-ref refid="app2" id="crosref0340">Figure S2</ce:cross-ref>G). Western blotting analysis confirmed the presence of high levels of p-TAU in neurons derived from TAU-152A/T-iPSCs or TAU-152T/T-iPSCs, which was dramatically decreased in neurons derived from TAU-152A/A-iPSCs (<ce:cross-ref refid="fig4" id="crosref0345">Figures 4</ce:cross-ref>L and 4M<ce:float-anchor refid="fig4"/>).</ce:para></ce:section><ce:section id="sec2.5" view="all"><ce:section-title id="sectitle0050">Genetic Correction of TAU-A152T Mutation Eliminates and Homozygous TAU-A152T Mutation Intensifies the Generation of Pathological TAU Fragments in Neurons</ce:section-title><ce:para id="p0085" view="all">We observed a greater degree of TAU fragmentation, as determined by western blotting using the antibody TAU-5, in neurons derived from TAU-152A/T-iPSCs than those derived from unrelated control iPSCs without the mutation (<ce:cross-ref refid="fig4" id="crosref0350">Figures 4</ce:cross-ref>A and 4B). More TAU fragmentation was also observed in brain samples from a patient with PSP carrying the TAU-A152T mutation than in those from a control subject without the variant (<ce:cross-ref refid="fig4" id="crosref0355">Figure 4</ce:cross-ref>C, arrows). Importantly, the mutation-related increase in TAU fragmentation in human iPSC-derived neurons was confirmed by western blotting with three different TAU antibodies (TAU-5, TAU-A12, and TAU-C17 that recognize the central core, N terminus, and C terminus of the protein, respectively) (<ce:cross-refs refid="bib3 bib31" id="crosrefs0070">Carmel et al., 1996; Porzig et al., 2007</ce:cross-refs>) and was decreased dramatically upon genetic correction of the mutation (<ce:cross-ref refid="fig4" id="crosref0360">Figures 4</ce:cross-ref>D-4I). The mutation-related increase in TAU fragmentation was confirmed in neurons derived from a subclone of TAU-152T/T-iPSCs (<ce:cross-ref refid="fig4" id="crosref0365">Figure 4</ce:cross-ref>D, 152T/T-2).</ce:para><ce:para id="p0090" view="all">Most strikingly, there was a mutant gene-dose-dependent increase in caspase-cleaved TAU fragments, as determined by the caspase-cleaved TAU-specific antibody C3 (<ce:cross-refs refid="bib9 bib11" id="crosrefs0075">Gamblin et al., 2003; Guillozet-Bongaarts et al., 2005</ce:cross-refs>), in neurons derived from the isogenic TAU-A152T-iPSCs (<ce:cross-ref refid="fig4" id="crosref0370">Figures 4</ce:cross-ref>J and 4K). In line with this observation, immunostaining with the TAU-C3 antibody revealed the accumulation of caspase-cleaved TAU in axons of neurons derived from TAU-152A/T-iPSCs and TAU-152T/T-iPSCs (<ce:cross-ref refid="fig3" id="crosref0375">Figures 3</ce:cross-ref>O and 3P) but not in those of neurons derived from TAU-152A/A-iPSCs (<ce:cross-ref refid="fig3" id="crosref0380">Figure 3</ce:cross-ref>N). The mutation-related accumulation of caspase-cleaved TAU was also observed in neurons derived from a subclone of TAU-152T/T-iPSCs (<ce:cross-ref refid="app2" id="crosref0385">Figure S2</ce:cross-ref>D). The numbers of caspase-cleaved TAU-positive neurons increased in a mutant gene-dose-dependent manner (<ce:cross-ref refid="fig3" id="crosref0390">Figure 3</ce:cross-ref>Q). We observed no caspase-cleaved TAU in GFAP-positive astrocytes (<ce:cross-ref refid="app2" id="crosref0395">Figure S2</ce:cross-ref>H). Likewise, caspase-cleaved TAU also accumulated in neuronal soma and axons in the patient with PSP carrying the TAU-A152T mutation (<ce:cross-ref refid="fig3" id="crosref0400">Figures 3</ce:cross-ref>R-3U).</ce:para></ce:section><ce:section id="sec2.6" view="all"><ce:section-title id="sectitle0055">Genetic Correction of TAU-A152T Eliminates the Detrimental Effects of the Mutation on Different Subtypes of Neurons</ce:section-title><ce:para id="p0095" view="all">We then determined the effects of the TAU-A152T mutation on different subtypes of neurons, including tyrosine-hydroxylase (TH)-positive dopaminergic neurons, T-box brain 1 (TBR1)-positive glutamatergic excitatory neurons (<ce:cross-ref refid="bib12" id="crosref0405">Hevner et al., 2001</ce:cross-ref>), and gamma-aminobutyric-acid (GABA)-positive inhibitory neurons. Strikingly, very low percentages of dopaminergic neurons were found in neuronal cultures from TAU-152A/T-iPSCs and TAU-152T/T-iPSCs (<ce:cross-ref refid="app2" id="crosref0410">Figures S2</ce:cross-ref>J-S2L). Genetic correction of the mutation increased the percentages of dopaminergic neurons by 4- to 8-fold (<ce:cross-ref refid="app2" id="crosref0415">Figures S2</ce:cross-ref>I-S2L), suggesting that dopaminergic neurons are especially vulnerable to TAU-A152T-induced neurotoxicity. Interestingly, the percentages of glutamatergic and GABAergic neurons were not significantly altered by the mutation (<ce:cross-ref refid="app2" id="crosref0420">Figures S2</ce:cross-ref>M-S2T). However, many glutamatergic (<ce:cross-ref refid="app2" id="crosref0425">Figure S2</ce:cross-ref>V) and GABAergic (<ce:cross-ref refid="app2" id="crosref0430">Figure S2</ce:cross-ref>X) neurons had abnormal morphologies, including neurite fragmentation/degeneration, which were also eliminated by genetic correction of the mutation (<ce:cross-ref refid="app2" id="crosref0435">Figures S2</ce:cross-ref>U and S2W).</ce:para></ce:section></ce:section><ce:section id="sec3" view="all"><ce:section-title id="sectitle0060">Discussion</ce:section-title><ce:para id="p0100" view="all">By combining the iPSC and ZFN-mediated gene-editing techniques, we generated "scarless" isogenic human iPSC lines carrying wild-type TAU or a heterozygous or homozygous TAU-A152T mutation. The use of genetically matched isogenic iPSC lines, with three gene doses of the mutation (zero, one, and two copies) on an identical genetic background, eliminates potential subject-to-subject and line-to-line variations of iPSCs and helps draw a clear conclusion regarding mutation-specific phenotypes. The isogenic TAU-iPSC lines generated in this study will be invaluable for further mechanistic studies of tauopathies and for related drug-screening efforts.</ce:para><ce:para id="p0105" view="all">Before the TAU-A152T mutation was identified in humans, it was widely accepted that mutations of TAU cause FTD and PSP, but not AD (<ce:cross-ref refid="bib15" id="crosref0440">Huang and Mucke, 2012</ce:cross-ref>). The TAU-A152T mutation is the first to show the association of a TAU mutation with increased risks for FTD, PSP, and AD (<ce:cross-ref refid="bib6" id="crosref0445">Coppola et al., 2012</ce:cross-ref>). Thus, the tauopathy model of human iPSCs, and the related molecular mechanisms identified in this study, should be applicable to all three tauopathy-related diseases for further mechanistic studies and drug screening.</ce:para><ce:para id="p0110" view="all">Although modeling neurodegenerative diseases with iPSCs has been reported (<ce:cross-refs refid="bib5 bib17 bib19 bib30 bib38" id="crosrefs0080">HD iPSC Consortium, 2012; Israel et al., 2012; Kondo et al., 2013; Park et al., 2008; Yamanaka, 2009</ce:cross-refs>), they typically recapitulate phenotypes reported in cell cultures or animal studies. Our study, however, identifies an unknown molecular mechanism underlying a disease-causing TAU mutation using isogenic iPSCs. A previous study reported that the TAU-A152T mutation increased soluble TAU oligomers and decreased microtubule-binding affinity of TAU in cell cultures and test tubes (<ce:cross-ref refid="bib6" id="crosref0450">Coppola et al., 2012</ce:cross-ref>). We demonstrate in iPSC-derived human neurons that this mutation predisposes TAU to proteolysis by caspase and other proteases, leading to tauopathy, axonal degeneration, and other related pathologies. We further demonstrate that correction of the mutation eliminates TAU proteolysis, indicating the specific effect of the mutation on TAU proteolysis. Our work therefore directly demonstrates that iPSCs, especially isogenic iPSCs, are a powerful tool not only for disease modeling but also for studies of disease mechanisms. Interestingly, dopaminergic neurons are especially vulnerable to TAU-A152T-induced neurotoxicity, which is in line with the observation that tauopathy in PSP is associated with excessive dopaminergic neuron loss (<ce:cross-ref refid="bib28" id="crosref0455">Murphy et al., 2008</ce:cross-ref>). The underlying mechanism remains to be determined.</ce:para></ce:section><ce:section id="sec4" role="materials-methods" view="all"><ce:section-title id="sectitle0065">Experimental Procedures</ce:section-title><ce:section id="sec4.1" view="all"><ce:section-title id="sectitle0070">Reprogramming Human Dermal Fibroblasts into iPSCs</ce:section-title><ce:para id="p0115" view="all">Fibroblasts were obtained from an individual carrying the TAU-A152T mutation in the <ce:italic>MAPT</ce:italic> gene. iPSCs were generated from early passages of fibroblasts by a retroviral reprogramming strategy with four factors (Oct4, Sox2, Klf4, and c-Myc) (<ce:cross-refs refid="bib35 bib34" id="crosrefs0085">Takahashi et al., 2007; Takahashi and Yamanaka, 2006</ce:cross-refs>). The animal procedure for testing teratoma formation was approved by the Gladstone Institutes and the University of California, San Francisco.</ce:para></ce:section><ce:section id="sec4.2" view="all"><ce:section-title id="sectitle0075">Preparation of ZFNs and Generation of Isogenic iPSC Lines</ce:section-title><ce:para id="p0120" view="all">A specific pair of five-finger ZFNs engineered to target a region ∼30 bp upstream of the A152T mutation site was prepared by Sigma. The ZFNs bound (uppercase) and cut (lowercase) the following sequence on the <ce:italic>MAPT</ce:italic> gene: CCCCTCTATCATGTTtcatttACAGGGGGCTGATGG. Isogenic TAU-A152T-iPSC lines were generated using this ZFN pair and a donor construct (<ce:cross-refs refid="bib1 bib7 bib24 bib33" id="crosrefs0090">An et al., 2012; Corti et al., 2012; Li et al., 2012; Soldner et al., 2011</ce:cross-refs>).</ce:para></ce:section><ce:section id="sec4.3" view="all"><ce:section-title id="sectitle0080">Neuronal Differentiation of iPSCs</ce:section-title><ce:para id="p0125" view="all">iPSCs were differentiated into neurons following a modified version of published protocols (<ce:cross-refs refid="bib4 bib14 bib32" id="crosrefs0095">Chambers et al., 2009; Hu and Zhang, 2009; Ring et al., 2012</ce:cross-refs>). Tauopathies were characterized by western blotting and immunocytochemistry with different TAU antibodies.</ce:para></ce:section><ce:section id="sec4.4" view="all"><ce:section-title id="sectitle0085">Human Neuropathology</ce:section-title><ce:para id="p0130" view="all">Tauopathies were characterized by western blotting and immunocytochemistry with different TAU antibodies on postmortem brain tissues from a 56-year-old woman with clinical and pathological PSP who carried the <ce:italic>MAPT</ce:italic> A152T variant and a 76-year-old man who died of prostate cancer without cognitive complaints.</ce:para></ce:section><ce:section id="sec4.5" view="all"><ce:section-title id="sectitle0090">Statistical Analyses</ce:section-title><ce:para id="p0135" view="all">Values are expressed as mean ± SD. Differences between means were assessed by t test or analysis of variance (ANOVA). p &lt; 0.05 was considered statistically significant.</ce:para><ce:para id="p0140" view="all">Detailed methods, including isogenic iPSC generation and characterization, neuronal differentiation, immunostaining, western blotting, and tauopathy analyses can be found in the <ce:cross-ref refid="app2" id="crosref0460">Supplemental Information</ce:cross-ref>.</ce:para></ce:section></ce:section></ce:sections><ce:acknowledgment id="ack0010" view="all"><ce:section-title id="sectitle0095">Acknowledgments</ce:section-title><ce:para id="p0145" view="all">This work was supported in part by Tau Consortium, grant RN2-00952 from the California Institute for Regenerative Medicine, grants AG022074, NS079725, and AG023501 from the National Institutes of Health, the Consortium for Frontotemporal Dementia Research, the S.D. Bechtel, Jr. Foundation, and the Roddenberry Foundation. We thank Gemma Rooney for technical advice, Anna Lisa Lucido and Gary Howard for editorial assistance, and Linda Turney for manuscript preparation.</ce:para></ce:acknowledgment><ce:appendices view="all"><ce:section id="app1" view="compact-standard"><ce:section-title id="sectitle0100">Supplemental Information</ce:section-title><ce:para id="p0150" view="all">Supplemental Information includes Supplemental Experimental Procedures, two figures, and one table and can be found with this article online at <ce:inter-ref xlink:href="doi:10.1016/j.stemcr.2013.08.001" id="intref0010" xlink:type="simple">http://dx.doi.org/10.1016/j.stemcr.2013.08.001</ce:inter-ref>.</ce:para></ce:section><ce:section id="app2" view="extended"><ce:section-title id="sectitle0105">Supplemental Information</ce:section-title><ce:para id="p0155" view="all"><ce:display><ce:e-component id="mmc1"><ce:label>Document S1. Supplemental Experimental Procedures, Figures S1 and S2, and Table S1</ce:label><ce:link locator="mmc1"/></ce:e-component></ce:display></ce:para></ce:section></ce:appendices></body><tail view="all"><ce:bibliography id="cebib0010" view="all"><ce:section-title id="sectitle0110">References</ce:section-title><ce:bibliography-sec id="cebibsec0010" view="all"><ce:bib-reference id="bib1"><ce:label>An et al., 2012</ce:label><sb:reference id="sref1"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.C.</ce:given-name><ce:surname>An</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Zhang</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Scott</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Montoro</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Wittkop</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Mooney</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Melov</ce:surname></sb:author><sb:author><ce:given-name>L.M.</ce:given-name><ce:surname>Ellerby</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell Stem Cell</sb:maintitle></sb:title><sb:volume-nr>11</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>253</sb:first-page><sb:last-page>263</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>Ashe and Zahs, 2010</ce:label><sb:reference id="sref2"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.H.</ce:given-name><ce:surname>Ashe</ce:surname></sb:author><sb:author><ce:given-name>K.R.</ce:given-name><ce:surname>Zahs</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Probing the biology of Alzheimer's disease in mice</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuron</sb:maintitle></sb:title><sb:volume-nr>66</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>631</sb:first-page><sb:last-page>645</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib3"><ce:label>Carmel et al., 1996</ce:label><sb:reference id="sref3"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Carmel</ce:surname></sb:author><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Mager</ce:surname></sb:author><sb:author><ce:given-name>L.I.</ce:given-name><ce:surname>Binder</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Kuret</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>271</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>32789</sb:first-page><sb:last-page>32795</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>Chambers et al., 2009</ce:label><sb:reference id="sref4"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Chambers</ce:surname></sb:author><sb:author><ce:given-name>C.A.</ce:given-name><ce:surname>Fasano</ce:surname></sb:author><sb:author><ce:given-name>E.P.</ce:given-name><ce:surname>Papapetrou</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Tomishima</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Sadelain</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Studer</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Biotechnol.</sb:maintitle></sb:title><sb:volume-nr>27</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>275</sb:first-page><sb:last-page>280</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>HD iPSC Consortium, 2012</ce:label><sb:reference id="sref5"><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>HD iPSC Consortium</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell Stem Cell</sb:maintitle></sb:title><sb:volume-nr>11</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>264</sb:first-page><sb:last-page>278</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>Coppola et al., 2012</ce:label><sb:reference id="sref6"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Coppola</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Chinnathambi</ce:surname></sb:author><sb:author><ce:given-name>J.J.</ce:given-name><ce:surname>Lee</ce:surname></sb:author><sb:author><ce:given-name>B.A.</ce:given-name><ce:surname>Dombroski</ce:surname></sb:author><sb:author><ce:given-name>M.C.</ce:given-name><ce:surname>Baker</ce:surname></sb:author><sb:author><ce:given-name>A.I.</ce:given-name><ce:surname>Soto-Ortolaza</ce:surname></sb:author><sb:author><ce:given-name>S.E.</ce:given-name><ce:surname>Lee</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Klein</ce:surname></sb:author><sb:author><ce:given-name>A.Y.</ce:given-name><ce:surname>Huang</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Sears</ce:surname></sb:author><sb:et-al/><sb:collaboration>Alzheimer's Disease Genetics Consortium</sb:collaboration></sb:authors><sb:title><sb:maintitle>Evidence for a role of the rare p.A152T variant in <ce:italic>MAPT</ce:italic> in increasing the risk for FTD-spectrum and Alzheimer's diseases</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Hum. Mol. Genet.</sb:maintitle></sb:title><sb:volume-nr>21</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>3500</sb:first-page><sb:last-page>3512</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>Corti et al., 2012</ce:label><sb:reference id="sref7"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Corti</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Nizzardo</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Simone</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Falcone</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Nardini</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Ronchi</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Donadoni</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Salani</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Riboldi</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Magri</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Sci. Transl. Med.</sb:maintitle></sb:title><sb:volume-nr>4</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue></sb:host><sb:comment>165ra162</sb:comment></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>Fong et al., 2011</ce:label><sb:reference id="sref8"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Fong</ce:surname></sb:author><sb:author><ce:given-name>K.A.</ce:given-name><ce:surname>Elliott</ce:surname></sb:author><sb:author><ce:given-name>L.F.</ce:given-name><ce:surname>Lock</ce:surname></sb:author><sb:author><ce:given-name>P.J.</ce:given-name><ce:surname>Donovan</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Nucleofection of human embryonic stem cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Methods Mol. Biol.</sb:maintitle></sb:title><sb:volume-nr>767</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>333</sb:first-page><sb:last-page>341</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>Gamblin et al., 2003</ce:label><sb:reference id="sref9"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.C.</ce:given-name><ce:surname>Gamblin</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Zambrano</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Abraha</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Lagalwar</ce:surname></sb:author><sb:author><ce:given-name>A.L.</ce:given-name><ce:surname>Guillozet</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Lu</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Fu</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Garcia-Sierra</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>LaPointe</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. USA</sb:maintitle></sb:title><sb:volume-nr>100</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>10032</sb:first-page><sb:last-page>10037</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>Goedert et al., 1989</ce:label><sb:reference id="sref10"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Goedert</ce:surname></sb:author><sb:author><ce:given-name>M.G.</ce:given-name><ce:surname>Spillantini</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Jakes</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Rutherford</ce:surname></sb:author><sb:author><ce:given-name>R.A.</ce:given-name><ce:surname>Crowther</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuron</sb:maintitle></sb:title><sb:volume-nr>3</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>519</sb:first-page><sb:last-page>526</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>Guillozet-Bongaarts et al., 2005</ce:label><sb:reference id="sref11"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.L.</ce:given-name><ce:surname>Guillozet-Bongaarts</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Garcia-Sierra</ce:surname></sb:author><sb:author><ce:given-name>M.R.</ce:given-name><ce:surname>Reynolds</ce:surname></sb:author><sb:author><ce:given-name>P.M.</ce:given-name><ce:surname>Horowitz</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Fu</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>M.E.</ce:given-name><ce:surname>Cahill</ce:surname></sb:author><sb:author><ce:given-name>E.H.</ce:given-name><ce:surname>Bigio</ce:surname></sb:author><sb:author><ce:given-name>R.W.</ce:given-name><ce:surname>Berry</ce:surname></sb:author><sb:author><ce:given-name>L.I.</ce:given-name><ce:surname>Binder</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurobiol. Aging</sb:maintitle></sb:title><sb:volume-nr>26</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>1015</sb:first-page><sb:last-page>1022</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>Hevner et al., 2001</ce:label><sb:reference id="sref12"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.F.</ce:given-name><ce:surname>Hevner</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Shi</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Justice</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Hsueh</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Sheng</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Smiga</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Bulfone</ce:surname></sb:author><sb:author><ce:given-name>A.M.</ce:given-name><ce:surname>Goffinet</ce:surname></sb:author><sb:author><ce:given-name>A.T.</ce:given-name><ce:surname>Campagnoni</ce:surname></sb:author><sb:author><ce:given-name>J.L.</ce:given-name><ce:surname>Rubenstein</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Tbr1 regulates differentiation of the preplate and layer 6</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuron</sb:maintitle></sb:title><sb:volume-nr>29</sb:volume-nr></sb:series><sb:date>2001</sb:date></sb:issue><sb:pages><sb:first-page>353</sb:first-page><sb:last-page>366</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>Hockemeyer et al., 2009</ce:label><sb:reference id="sref13"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Hockemeyer</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Soldner</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Beard</ce:surname></sb:author><sb:author><ce:given-name>Q.</ce:given-name><ce:surname>Gao</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Mitalipova</ce:surname></sb:author><sb:author><ce:given-name>R.C.</ce:given-name><ce:surname>DeKelver</ce:surname></sb:author><sb:author><ce:given-name>G.E.</ce:given-name><ce:surname>Katibah</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Amora</ce:surname></sb:author><sb:author><ce:given-name>E.A.</ce:given-name><ce:surname>Boydston</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Zeitler</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Biotechnol.</sb:maintitle></sb:title><sb:volume-nr>27</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>851</sb:first-page><sb:last-page>857</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib14"><ce:label>Hu and Zhang, 2009</ce:label><sb:reference id="sref14"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>B.Y.</ce:given-name><ce:surname>Hu</ce:surname></sb:author><sb:author><ce:given-name>S.C.</ce:given-name><ce:surname>Zhang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Differentiation of spinal motor neurons from pluripotent human stem cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Protoc.</sb:maintitle></sb:title><sb:volume-nr>4</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>1295</sb:first-page><sb:last-page>1304</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib15"><ce:label>Huang and Mucke, 2012</ce:label><sb:reference id="sref15"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Huang</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Mucke</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Alzheimer mechanisms and therapeutic strategies</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>148</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>1204</sb:first-page><sb:last-page>1222</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib16"><ce:label>Hutton, 2000</ce:label><sb:reference id="sref16"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Hutton</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Molecular genetics of chromosome 17 tauopathies</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. N Y Acad. Sci.</sb:maintitle></sb:title><sb:volume-nr>920</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>63</sb:first-page><sb:last-page>73</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib17"><ce:label>Israel et al., 2012</ce:label><sb:reference id="sref17"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.A.</ce:given-name><ce:surname>Israel</ce:surname></sb:author><sb:author><ce:given-name>S.H.</ce:given-name><ce:surname>Yuan</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Bardy</ce:surname></sb:author><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Reyna</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Mu</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Herrera</ce:surname></sb:author><sb:author><ce:given-name>M.P.</ce:given-name><ce:surname>Hefferan</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Van Gorp</ce:surname></sb:author><sb:author><ce:given-name>K.L.</ce:given-name><ce:surname>Nazor</ce:surname></sb:author><sb:author><ce:given-name>F.S.</ce:given-name><ce:surname>Boscolo</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>482</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>216</sb:first-page><sb:last-page>220</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib18"><ce:label>Kara et al., 2012</ce:label><sb:reference id="sref18"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Kara</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Ling</ce:surname></sb:author><sb:author><ce:given-name>A.M.</ce:given-name><ce:surname>Pittman</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Shaw</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>de Silva</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Simone</ce:surname></sb:author><sb:author><ce:given-name>J.L.</ce:given-name><ce:surname>Holton</ce:surname></sb:author><sb:author><ce:given-name>J.D.</ce:given-name><ce:surname>Warren</ce:surname></sb:author><sb:author><ce:given-name>J.D.</ce:given-name><ce:surname>Rohrer</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Xiromerisiou</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurobiol. Aging</sb:maintitle></sb:title><sb:volume-nr>33</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>e7</sb:first-page></sb:pages></sb:host><sb:comment>e14</sb:comment></sb:reference></ce:bib-reference><ce:bib-reference id="bib19"><ce:label>Kondo et al., 2013</ce:label><sb:reference id="sref19"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Kondo</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Asai</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Tsukita</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Kutoku</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Ohsawa</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Sunada</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Imamura</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Egawa</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Yahata</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Okita</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell Stem Cell</sb:maintitle></sb:title><sb:volume-nr>12</sb:volume-nr></sb:series><sb:date>2013</sb:date></sb:issue><sb:pages><sb:first-page>487</sb:first-page><sb:last-page>496</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib20"><ce:label>Kosik et al., 1986</ce:label><sb:reference id="sref20"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.S.</ce:given-name><ce:surname>Kosik</ce:surname></sb:author><sb:author><ce:given-name>C.L.</ce:given-name><ce:surname>Joachim</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Selkoe</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. USA</sb:maintitle></sb:title><sb:volume-nr>83</sb:volume-nr></sb:series><sb:date>1986</sb:date></sb:issue><sb:pages><sb:first-page>4044</sb:first-page><sb:last-page>4048</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib21"><ce:label>Kosik et al., 1989</ce:label><sb:reference id="sref21"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.S.</ce:given-name><ce:surname>Kosik</ce:surname></sb:author><sb:author><ce:given-name>L.D.</ce:given-name><ce:surname>Orecchio</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Bakalis</ce:surname></sb:author><sb:author><ce:given-name>R.L.</ce:given-name><ce:surname>Neve</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Developmentally regulated expression of specific tau sequences</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuron</sb:maintitle></sb:title><sb:volume-nr>2</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>1389</sb:first-page><sb:last-page>1397</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib22"><ce:label>Kovacs et al., 2011</ce:label><sb:reference id="sref22"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.G.</ce:given-name><ce:surname>Kovacs</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Wöhrer</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Ströbel</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Botond</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Attems</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Budka</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Unclassifiable tauopathy associated with an A152T variation in MAPT exon 7</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin. Neuropathol.</sb:maintitle></sb:title><sb:volume-nr>30</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>3</sb:first-page><sb:last-page>10</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib23"><ce:label>Lee et al., 2001</ce:label><sb:reference id="sref23"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>V.M.-Y.</ce:given-name><ce:surname>Lee</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Goedert</ce:surname></sb:author><sb:author><ce:given-name>J.Q.</ce:given-name><ce:surname>Trojanowski</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Neurodegenerative tauopathies</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Annu. Rev. Neurosci.</sb:maintitle></sb:title><sb:volume-nr>24</sb:volume-nr></sb:series><sb:date>2001</sb:date></sb:issue><sb:pages><sb:first-page>1121</sb:first-page><sb:last-page>1159</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib24"><ce:label>Li et al., 2012</ce:label><sb:reference id="sref24"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.B.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>K.H.</ce:given-name><ce:surname>Chang</ce:surname></sb:author><sb:author><ce:given-name>P.R.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>R.K.</ce:given-name><ce:surname>Hirata</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Papayannopoulou</ce:surname></sb:author><sb:author><ce:given-name>D.W.</ce:given-name><ce:surname>Russell</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Trisomy correction in Down syndrome induced pluripotent stem cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell Stem Cell</sb:maintitle></sb:title><sb:volume-nr>11</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>615</sb:first-page><sb:last-page>619</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib25"><ce:label>Mandelkow and Mandelkow, 2012</ce:label><sb:reference id="sref25"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Mandelkow</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Mandelkow</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Biochemistry and cell biology of tau protein in neurofibrillary degeneration</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cold Spring Harb Perspect Med</sb:maintitle></sb:title><sb:volume-nr>2</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>a006247</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib26"><ce:label>Miller et al., 2007</ce:label><sb:reference id="sref26"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Miller</ce:surname></sb:author><sb:author><ce:given-name>M.C.</ce:given-name><ce:surname>Holmes</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>D.Y.</ce:given-name><ce:surname>Guschin</ce:surname></sb:author><sb:author><ce:given-name>Y.L.</ce:given-name><ce:surname>Lee</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Rupniewski</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Beausejour</ce:surname></sb:author><sb:author><ce:given-name>A.J.</ce:given-name><ce:surname>Waite</ce:surname></sb:author><sb:author><ce:given-name>N.S.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>K.A.</ce:given-name><ce:surname>Kim</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>An improved zinc-finger nuclease architecture for highly specific genome editing</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Biotechnol.</sb:maintitle></sb:title><sb:volume-nr>25</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>778</sb:first-page><sb:last-page>785</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib27"><ce:label>Morris et al., 2011</ce:label><sb:reference id="sref27"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Morris</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Maeda</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Vossel</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Mucke</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The many faces of tau</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuron</sb:maintitle></sb:title><sb:volume-nr>70</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>410</sb:first-page><sb:last-page>426</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib28"><ce:label>Murphy et al., 2008</ce:label><sb:reference id="sref28"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.E.</ce:given-name><ce:surname>Murphy</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Karaconji</ce:surname></sb:author><sb:author><ce:given-name>C.D.</ce:given-name><ce:surname>Hardman</ce:surname></sb:author><sb:author><ce:given-name>G.M.</ce:given-name><ce:surname>Halliday</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Excessive dopamine neuron loss in progressive supranuclear palsy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mov. Disord.</sb:maintitle></sb:title><sb:volume-nr>23</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>607</sb:first-page><sb:last-page>610</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib29"><ce:label>Neve et al., 1986</ce:label><sb:reference id="sref29"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.L.</ce:given-name><ce:surname>Neve</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Harris</ce:surname></sb:author><sb:author><ce:given-name>K.S.</ce:given-name><ce:surname>Kosik</ce:surname></sb:author><sb:author><ce:given-name>D.M.</ce:given-name><ce:surname>Kurnit</ce:surname></sb:author><sb:author><ce:given-name>T.A.</ce:given-name><ce:surname>Donlon</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Res.</sb:maintitle></sb:title><sb:volume-nr>387</sb:volume-nr></sb:series><sb:date>1986</sb:date></sb:issue><sb:pages><sb:first-page>271</sb:first-page><sb:last-page>280</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib30"><ce:label>Park et al., 2008</ce:label><sb:reference id="sref30"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>I.-H.</ce:given-name><ce:surname>Park</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Arora</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Huo</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Maherali</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Ahfeldt</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Shimamura</ce:surname></sb:author><sb:author><ce:given-name>M.W.</ce:given-name><ce:surname>Lensch</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Cowan</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Hochedlinger</ce:surname></sb:author><sb:author><ce:given-name>G.Q.</ce:given-name><ce:surname>Daley</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Disease-specific induced pluripotent stem cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>134</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>877</sb:first-page><sb:last-page>886</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib31"><ce:label>Porzig et al., 2007</ce:label><sb:reference id="sref31"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Porzig</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Singer</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Hoffmann</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochem. Biophys. Res. Commun.</sb:maintitle></sb:title><sb:volume-nr>358</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>644</sb:first-page><sb:last-page>649</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib32"><ce:label>Ring et al., 2012</ce:label><sb:reference id="sref32"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.L.</ce:given-name><ce:surname>Ring</ce:surname></sb:author><sb:author><ce:given-name>L.M.</ce:given-name><ce:surname>Tong</ce:surname></sb:author><sb:author><ce:given-name>M.E.</ce:given-name><ce:surname>Balestra</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Javier</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Andrews-Zwilling</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Walker</ce:surname></sb:author><sb:author><ce:given-name>W.R.</ce:given-name><ce:surname>Zhang</ce:surname></sb:author><sb:author><ce:given-name>A.C.</ce:given-name><ce:surname>Kreitzer</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Huang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell Stem Cell</sb:maintitle></sb:title><sb:volume-nr>11</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>100</sb:first-page><sb:last-page>109</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib33"><ce:label>Soldner et al., 2011</ce:label><sb:reference id="sref33"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Soldner</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Laganière</ce:surname></sb:author><sb:author><ce:given-name>A.W.</ce:given-name><ce:surname>Cheng</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Hockemeyer</ce:surname></sb:author><sb:author><ce:given-name>Q.</ce:given-name><ce:surname>Gao</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Alagappan</ce:surname></sb:author><sb:author><ce:given-name>V.</ce:given-name><ce:surname>Khurana</ce:surname></sb:author><sb:author><ce:given-name>L.I.</ce:given-name><ce:surname>Golbe</ce:surname></sb:author><sb:author><ce:given-name>R.H.</ce:given-name><ce:surname>Myers</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Lindquist</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>146</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>318</sb:first-page><sb:last-page>331</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib34"><ce:label>Takahashi and Yamanaka, 2006</ce:label><sb:reference id="sref34"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Takahashi</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Yamanaka</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>126</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>663</sb:first-page><sb:last-page>676</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib35"><ce:label>Takahashi et al., 2007</ce:label><sb:reference id="sref35"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Takahashi</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Tanabe</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Ohnuki</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Narita</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Ichisaka</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Tomoda</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Yamanaka</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>131</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>861</sb:first-page><sb:last-page>872</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib36"><ce:label>Vossel and Miller, 2008</ce:label><sb:reference id="sref36"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.A.</ce:given-name><ce:surname>Vossel</ce:surname></sb:author><sb:author><ce:given-name>B.L.</ce:given-name><ce:surname>Miller</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>New approaches to the treatment of frontotemporal lobar degeneration</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Curr. Opin. Neurol.</sb:maintitle></sb:title><sb:volume-nr>21</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>708</sb:first-page><sb:last-page>716</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib37"><ce:label>Weder et al., 2007</ce:label><sb:reference id="sref37"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.D.</ce:given-name><ce:surname>Weder</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Aziz</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Wilkins</ce:surname></sb:author><sb:author><ce:given-name>R.R.</ce:given-name><ce:surname>Tampi</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Frontotemporal dementias: a review</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Gen. Psychiatry</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>15</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib38"><ce:label>Yamanaka, 2009</ce:label><sb:reference id="sref38"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Yamanaka</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A fresh look at iPS cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>137</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>13</sb:first-page><sb:last-page>17</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article></xocs:serial-item></xocs:doc>
